

Level 2, 66 Hunter Street  
Sydney NSW 2000  
Tel: (61-2) 9300 3344  
Fax: (61-2) 9221 6333  
E-mail: [mmora@miscorp.com.au](mailto:mmora@miscorp.com.au)  
Website: [www.biotron.com.au](http://www.biotron.com.au)

30 March 2026

The Manager Companies  
ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

(3 pages by email)

Dear Sir / Madam

### APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board of Biotron Limited ('Biotron' or the 'Company') is pleased to announce the appointment of Graeme Wald as Non-Executive Director, effective today.

Graeme is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst and while at Merrill Lynch was rated the top analyst in the Pharmaceuticals and Healthcare sector in South Africa and was a member of the top-rated Global Paper & Pulp research team. In Australia he played a leading role in growing Wilson HTM's Life Science business to the largest in the country while Head of Lifescience research. He has extensive experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures.

He has played a major role in raising more than \$750M for companies in the sector and was Chairman of the Risk & Audit Committee of Nexvet Inc. while a director of the company through to its NASDAQ listing. He was also founding Chairman of Prota Therapeutics Pty Ltd and acting CEO. He is also CEO and Director of MyrioTherapeutics Pty Ltd, a Melbourne based antibody drug company developing novel antibodies for the treatment of solid tumours and is Chairman of Psiao Therapeutics, also Melbourne based that is developing novel antibodies for the treatment of prostate cancer based on Myrio technology. He is Chairman of US based Hula Therapeutics, a private company in the clinical stage of developing a treatment for paediatric neuroblastoma, using technology partly developed by Myrio

Biotron's Chairman, Michael Hoy said "Graeme Wald is a welcome addition to the Biotron Board. He adds substantial expertise and experience at an important stage of the Company's new project developments."

In accordance with Listing Rule 3.19A, I attach an Appendix 3X, Initial Director's Interest Notice, for Graeme Wald.

This announcement has been approved by Biotron Board of Directors.

Yours faithfully,



Michelle Miller  
Managing Director

# Appendix 3X

## Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

|                       |                        |
|-----------------------|------------------------|
| <b>Name of entity</b> | <b>BIOTRON LIMITED</b> |
| <b>ABN</b>            | <b>60 086 399 144</b>  |

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |               |
|----------------------------|---------------|
| <b>Name of Director</b>    | GRAEME WALD   |
| <b>Date of appointment</b> | 30 MARCH 2026 |

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| <b>Number &amp; class of securities</b> |                 |
|---|-----------------|
| 497                                     | Ordinary Shares |

+ See chapter 19 for defined terms.

**Part 2 – Director's relevant interests in securities of which the director is not the registered holder**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

| <b>Name of holder &amp; nature of interest</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | <b>Number &amp; class of Securities</b>                             |
|---|---|
| Zebra235 Pty Ltd <Zebra235 A/C><br>(Where the director holds a beneficial interest)   | 97,675,714 Ordinary fully paid shares<br>97,676 Performance shares. |

**Part 3 – Director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |     |
|--|-----|
| <b>Detail of contract</b>  | N/A |
| <b>Nature of interest</b>  | N/A |
| <b>Name of registered holder<br/>(if issued securities)</b>      | N/A |
| <b>No. and class of securities to which interest<br/>relates</b> | N/A |

+ See chapter 19 for defined terms.